Cerebrospinal fluid lymphocytosis: a hallmark of neurological complications during checkpoint inhibition.

Subjects

Subjects :

Adult
Aged
Antibodies, Monoclonal, Humanized administration & dosage
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Cell Cycle Checkpoints drug effects
Cell Cycle Checkpoints immunology
Female
Humans
Immunosuppressive Agents adverse effects
Immunosuppressive Agents therapeutic use
Ipilimumab administration & dosage
Lymphocytosis diagnosis
Male
Middle Aged
Neoplasms cerebrospinal fluid
Neoplasms drug therapy
Neoplasms pathology
Nervous System Diseases cerebrospinal fluid
Nervous System Diseases chemically induced
Nervous System Diseases diagnosis
Neurotoxicity Syndromes cerebrospinal fluid
Neurotoxicity Syndromes etiology
Nivolumab administration & dosage
Protein Kinase Inhibitors adverse effects
Protein Kinase Inhibitors therapeutic use
Retrospective Studies
Severity of Illness Index
Antibodies, Monoclonal, Humanized adverse effects
Ipilimumab adverse effects
Lymphocytosis cerebrospinal fluid
Lymphocytosis chemically induced
Neurotoxicity Syndromes diagnosis
Nivolumab adverse effects

Details

Language :

English

ISSN :

1879-0852

Volume :

121

Database :

MEDLINE

Journal :

European journal of cancer (Oxford, England : 1990)

Publication Type :

Report

Accession number :

31522128

Full Text :

https://doi.org/10.1016/j.ejca.2019.08.004